v
CONTENTS 1 2 7 2 14 COLUMN 15 RAGEAGEs 21 COLUMN 22 26 COLUMN NADPH 28 32 COLUMN GLP1 36 39 COLUMN AGEs 44 46 54 COLUMN GWAS 55 59 3 66 COLUMN 69 COLUMN 1 2 71 vi
4 78 84 89 COLUMN GFR decliner 92 94 5 remission 100 107 1 113 RAS 117 2 121 COLUMN 124 COLUMN 127 128 COLUMN RhoRho 132 134 COLUMN 137 2 139 1 146 COLUMN diabetic cardiomyopathy 147 COLUMN 148 2 154 vii
3 162 COLUMN Hb ESA Hb 165 168 172 176 COLUMN 177 182 COLUMN nephrogenic systemic fibrosisnsf 186 188 COLUMN FROMJ JDOIT2 189 6 196 COLUMN vacuolar H ATPase 200 Nrf2 203 COLUMN 207 209 215 SIRT1 219 HIF1 225 COLUMN HIF1 229 mtor 231 COLUMN mtor 232 236 239 viii
ix
x
Quick Index p.2 p.7 p.78 p.84p.89 p.94 p.66 p.100 p.107p.113117121p.128 p.134 p.182 p.139 p.146 p.154 p.162 p.168 p.172 p.176 p.188 p 113 117 121 139 1 188 1 p.182 xi
Quick Index 1 ACCOMPLISHAvoiding cardiovascular events through combination therapy in patients living with systolic hypertension 11,506 trial ACE Ca 125152 ACCORD LipidAction to control cardio vascular risk in diabetes lipid trial 2 5,518 131 ACCORDAction to control cardiovascu lar risk in diabetes 2 10,251 100109 121 ADVANCEAction in diabetes and vascu lar diseasepreterax and diamicron modi fiedrelease controlled evaluation 20 215 55 2 11,140 914 96109 ALLHATAntihypertensive and lipidlow ering treatment to prevent heart attack trial 33,357 Ca ACE 120125 ALTITUDEAliskiren trial in type 2 diabe tes using cardiorenal endpoints ACE ARB 2 8,600 ACE ARB 100125 ASUCA Assessment of clinical useful ness in CKD patients with atorvastatin CKD egfr 131 AURORAA study to evaluate the use of rosuvastatin in subjects on regular hemo dialysisan assessment of survival and cardiovascular events 5080 2,776 131 BENEDICTBergamo nephrologic diabe tes complications trial 2 1,209 Ca ACE 117 CARECholesterol and recurrent events trial 4,159 129 CASEJCandesartan antihypertensive survival evaluation in Japantrial 1 4,728 ARB Ca 120 CHOIRCorrection of hemoglobin and outcomes in renal insufficiencytrial CKD 1,432 13.5gdL 11.3gdL 2 165 Chronic kidney disease Japan cohort study CKD 3,000 CKD 162 CORE Collaborative organization of rheothrx evaluation 2,948 148 xii
CREATEThe cardiovascular risk reduc tion by early anemia treatment with epoe tin beta DAISDiabetes atherosclerosis interven tion study DCCTDiabetes control and complica tions trial DNETTJapanDiabetic nephropathy re mission and regression team trial in Ja pan EDICEpidemiology of diabetes interven tion and complications EMERALDEnhanced myocardial effica cy and recovery by aspiration of liberated debris EUCLIDEURODIAB controlled trial of lisinopril in insulindependent diabetes mellitus FIELD Fenofibrate intervention and event lowering in diabetes CKD 600 2 418 1 1,441 2 600 DCCT 1,302 18 501 34 CKD 165 DCCT PCI 1 530 ACE 2 9,795 131 15107 188 107 148 117 131 4D German diabetes and dialysis studydie deutsche diabetes dialyse 2 1,255 131 FROMJThe frontier of renal outcome modifications in Japan 40 74 CKD 3 188 GUARDGauging albuminuria reduction with lotrel in diabetic patients with hyper tension 2 332 ACE Ca 125 HOPE Heart outcomes prevention evaluation study HOTHypertension optimal treatment study 55 ACE 3,577 5080 100150mmHg 18,790 ACE 151 114 IDEALInitiating dialysis early and late 18 CKD 828 CKD 169 xiii
Quick Index p.14 NO NADHDAG AGEs p.21 AGEs RAGEAGEs NFB DAGPKC DAGPKC PKC enoset1 VEGF TGF NFB NADPH p.26 DNA Ang II TGFPAI1 enos p.32 ICAM1 p.54 SLC12A3ELMO1 NCALDACACB p.59 PKCNFB RAGE Ang IITGF1 ROS p.196 Nrf2p.203 p.209 p.215sirt1p.219hif1 p.225mtorp.231 p.46 TGF VEGF p.39 GFR hyperfilterration xvi
1015 2 7
1 8
MEMO hospitalbased study popula tionbased study 9
1 GFR2 MEMO HDL HDL 10
2 139
5 140
2 141
5 1994 ACE 2 4 1 g 1 1 12 63 12 1995 1 2 150 cm 47 kg 16478 mmhghba1cngsp9.5 46 g 2.6 gdl Ccr68 ml ACE Ca 30 4 0.10.5 g ACE Ccr 43 ml 1 HbA1c NGSP 6.46.9 2 6.4 5 2 3 4 1998 12 2000 1 1 Ccr 19961997 30 ml 4050 ml 142
DTP 113866612514 TEL0338131100001305196565 http://www.nakayamashoten.co.jp/ ISBN978-4-521-73382-1 Published by Nakayama Shoten Co., Ltd. Printed in Japan